Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of ALZT-OP1 in Healthy Volunteers
NCT02482324Phase 1Completed
- Sponsor
- AZTherapies
- Start
- Jun 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sodium cromoglycate and ibuprofen in Alzheimer's disease (AD) (2 arms), sponsored by AZTherapies. Primary endpoint: Non-compartmental plasma pharmacokinetics for ALZT-OP1a and ALZT-OP1b. Started Jun 2015; status: completed.
02
Drugs
sodium cromoglycateibuprofen
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02482324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02482324.